| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1875-5364(20)30003-0 |
| P698 | PubMed publication ID | 31955822 |
| P2093 | author name string | Wei Guo | |
| Cong Chen | |||
| Wen Lei | |||
| Qian-Wen Li | |||
| P2860 | cites work | Damage of the lateral geniculate nucleus in MS: Assessing the missing node of the visual pathway | Q93010979 |
| The product of the H19 gene may function as an RNA | Q24599284 | ||
| Disease modifying therapies for relapsing multiple sclerosis | Q26739903 | ||
| Long non-coding RNAs as novel targets for therapy in hepatocellular carcinoma | Q26751346 | ||
| Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes | Q26776234 | ||
| Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis | Q26781285 | ||
| Molecular and Cellular Mechanisms of Action of Tumour Suppressor GAS5 LncRNA | Q26801277 | ||
| Biomarkers in prostate cancer: what's new? | Q27026210 | ||
| Basic biology and therapeutic implications of lncRNA | Q28080732 | ||
| The mechanism of action of interferon-β in relapsing multiple sclerosis | Q28239752 | ||
| Multiple sclerosis | Q28299151 | ||
| An improved zinc-finger nuclease architecture for highly specific genome editing | Q28307951 | ||
| Risk alleles for multiple sclerosis identified by a genomewide study | Q29614890 | ||
| Human β cell transcriptome analysis uncovers lncRNAs that are tissue-specific, dynamically regulated, and abnormally expressed in type 2 diabetes | Q30416868 | ||
| Integrating genome-wide association studies and gene expression data highlights dysregulated multiple sclerosis risk pathways | Q31098740 | ||
| PRC2 is dispensable for HOTAIR-mediated transcriptional repression | Q33563215 | ||
| The human long noncoding RNA lnc-IL7R regulates the inflammatory response | Q33934251 | ||
| A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis | Q34093899 | ||
| Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia | Q34213539 | ||
| Regulation of the Th1 genomic locus from Ifng through Tmevpg1 by T-bet | Q34289462 | ||
| Epigenetic aspects of rheumatoid arthritis: contribution of non-coding RNAs. | Q34553125 | ||
| Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. | Q34596171 | ||
| Long non-coding RNAs and control of gene expression in the immune system | Q34616243 | ||
| Development of oral cladribine for the treatment of multiple sclerosis | Q35013390 | ||
| From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease | Q35024083 | ||
| Aptamers: active targeting ligands for cancer diagnosis and therapy | Q35086493 | ||
| Multiple Sclerosis: Pathogenesis and Treatment | Q35151851 | ||
| Towards a therapy for Angelman syndrome by targeting a long non-coding RNA. | Q35154104 | ||
| Noncoding RNA gene silencing through genomic integration of RNA destabilizing elements using zinc finger nucleases | Q35493908 | ||
| Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. | Q35632848 | ||
| Inhibition of System Xc(-) Transporter Attenuates Autoimmune Inflammatory Demyelination | Q35815842 | ||
| Protection against Th17 cells differentiation by an interleukin-23 receptor cytokine-binding homology region | Q36247264 | ||
| Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis | Q36429919 | ||
| Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling | Q36435673 | ||
| Expression Analysis of Long Non-coding RNAs in the Blood of Multiple Sclerosis Patients | Q47887903 | ||
| Interferon-beta mechanisms of action in multiple sclerosis | Q48320110 | ||
| Suppression of human and mouse Th17 differentiation and autoimmunity by an endogenous Interleukin 23 receptor cytokine-binding homology region | Q48509247 | ||
| The role of long non-coding RNAs in rheumatic diseases | Q49596604 | ||
| Functional network analysis reveals biological roles of lncRNAs and mRNAs in MOG35-55 specific CD4+T helper cells | Q49792957 | ||
| Soluble Interleukin-7 receptor levels and risk of acute graft-versus-disease after allogeneic haematopoietic stem cell transplantation | Q50232912 | ||
| Effect of Circular ANRIL on the Inflammatory Response of Vascular Endothelial Cells in a Rat Model of Coronary Atherosclerosis | Q50542526 | ||
| The expression of lnc-IL-7R long non-coding RNA dramatically correlated with soluble and membrane-bound isoforms of IL-7Ra gene in multiple sclerosis patients | Q50906066 | ||
| Involvement of lncRNA-1700040D17Rik in Th17 cell differentiation and the pathogenesis of EAE. | Q51064728 | ||
| Linc-MAF-4 regulates Th1/Th2 differentiation and is associated with the pathogenesis of multiple sclerosis by targeting MAF. | Q51322775 | ||
| STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner. | Q52655496 | ||
| Analysis of Long Noncoding RNA and mRNA Expression Profiles in IL-9-Activated Astrocytes and EAE Mice. | Q52666431 | ||
| Roles of the Chr.9p21.3 ANRIL Locus in Regulating Inflammation and Implications for Anti-Inflammatory Drug Target Identification. | Q55078607 | ||
| Knockdown of the Herpes Simplex Virus 1 Latency-Associated Transcript Reduces Reactivation from Latency | Q59359652 | ||
| The Diversity of Encephalitogenic CD4+ T Cells in Multiple Sclerosis and Its Animal Models | Q61812996 | ||
| Multiple sclerosis | Q61861830 | ||
| Long non-coding RNAs in cancer: implications for personalized therapy | Q62083228 | ||
| Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options | Q82917018 | ||
| PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis | Q87660291 | ||
| Association Study of ANRIL Genetic Variants and Multiple Sclerosis | Q88528129 | ||
| Sulfasalazine alters microglia phenotype by competing endogenous RNA effect of miR-136-5p and long non-coding RNA HOTAIR in cuprizone-induced demyelination | Q89259862 | ||
| Multiple sclerosis genetics | Q89808094 | ||
| Implications of the noncoding RNAs in rheumatoid arthritis pathogenesis | Q90705027 | ||
| Dysregulation of long non-coding RNA profile in peripheral blood of multiple sclerosis patients | Q90981928 | ||
| LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients | Q91252989 | ||
| GM-CSF and CXCR4 define a T helper cell signature in multiple sclerosis | Q92094134 | ||
| Down-regulation of taurine-up-regulated gene 1 attenuates inflammation by sponging miR-9-5p via targeting NF-κB1/p50 in multiple sclerosis | Q92499734 | ||
| Distinct Expression of Inflammatory Features in T Helper 17 Cells from Multiple Sclerosis Patients | Q92543418 | ||
| Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets | Q36669117 | ||
| Long non-coding RNA ANRIL regulates inflammatory responses as a novel component of NF-κB pathway | Q36791595 | ||
| Multiple sclerosis: a complicated picture of autoimmunity. | Q36915907 | ||
| Class II HLA interactions modulate genetic risk for multiple sclerosis | Q36920509 | ||
| Development of targeted therapy for ovarian cancer mediated by a plasmid expressing diphtheria toxin under the control of H19 regulatory sequences | Q37325540 | ||
| Expression Profile of Long Noncoding RNAs in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients | Q37345588 | ||
| Immunosuppressive therapies for inflammatory bowel disease | Q37660661 | ||
| T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. | Q37777431 | ||
| Long non-coding RNAs: challenges for diagnosis and therapies | Q38079887 | ||
| Targeting long non-coding RNA to therapeutically upregulate gene expression | Q38110692 | ||
| Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis | Q38111620 | ||
| Differential effects of genetic susceptibility factors in males and females with multiple sclerosis | Q38116642 | ||
| Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects | Q38141840 | ||
| The current role of mitoxantrone in the treatment of multiple sclerosis | Q38212259 | ||
| Teriflunomide (Aubagio®) for the treatment of multiple sclerosis | Q38219938 | ||
| LncRNA: a link between RNA and cancer | Q38243587 | ||
| Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation | Q38245158 | ||
| Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides. | Q38308838 | ||
| Functional genomics of the CDKN2A/B locus in cardiovascular and metabolic disease: what have we learned from GWASs? | Q38368484 | ||
| Antisense oligonucleotides in therapy for neurodegenerative disorders | Q38386597 | ||
| Emerging role of long noncoding RNAs in autoimmune diseases. | Q38491550 | ||
| 2-Benzamido-3-(4-bromophenyl) acrylic acid | Q38549056 | ||
| Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets? | Q38769281 | ||
| lncRNA directs cooperative epigenetic regulation downstream of chemokine signals | Q38938483 | ||
| Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis | Q38987093 | ||
| Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies | Q39041003 | ||
| miRNA and lncRNA as biomarkers in cholangiocarcinoma(CCA). | Q39443955 | ||
| Human Epistatic Interaction Controls IL7R Splicing and Increases Multiple Sclerosis Risk. | Q40275029 | ||
| Update on disease-modifying therapies for multiple sclerosis | Q40355402 | ||
| Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis | Q40400262 | ||
| The long intergenic noncoding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. | Q42084982 | ||
| Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy | Q42214388 | ||
| LncRNA GAS5 inhibits microglial M2 polarization and exacerbates demyelination. | Q42288426 | ||
| Monoclonal antibodies targeting CD20. | Q42906640 | ||
| Flows and flaws in primary central nervous system lymphoma | Q42940913 | ||
| Long non-coding RNAs in rheumatoid arthritis | Q47234180 | ||
| HOTAIR but not ANRIL long non-coding RNA contributes to the pathogenesis of multiple sclerosis | Q47797228 | ||
| Drugs approved for the treatment of multiple sclerosis: review of their safety profile. | Q47868767 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 36-46 | |
| P577 | publication date | 2020-01-01 | |
| P1476 | title | Recent advances of long noncoding RNAs involved in the development of multiple sclerosis | |
| P478 | volume | 18 |
Search more.